Segui
Jonathan Pol
Jonathan Pol
INSERM, Centre de Recherche des Cordeliers (Paris), Gustave Roussy Cancer Campus (Villejuif)
Email verificata su inserm.fr
Titolo
Citata da
Citata da
Anno
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
8312014
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
4842016
First oncolytic virus approved for melanoma immunotherapy
J Pol, G Kroemer, L Galluzzi
Oncoimmunology 5 (1), e1115641, 2016
3462016
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008866, 2015
3002015
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
P Liu, L Zhao, J Pol, S Levesque, A Petrazzuolo, C Pfirschke, C Engblom, ...
Nature communications 10 (1), 1486, 2019
2302019
The molecular hallmarks of the serrated pathway in colorectal cancer
FDE De Palma, V D’argenio, J Pol, G Kroemer, MC Maiuri, F Salvatore
Cancers 11 (7), 1017, 2019
1952019
Maraba virus as a potent oncolytic vaccine vector
JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, ...
Molecular therapy 22 (2), 420-429, 2014
1932014
Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies
S Gujar, JG Pol, Y Kim, PW Lee, G Kroemer
Trends in immunology 39 (3), 209-221, 2018
1762018
Trial watch: peptide-based vaccines in anticancer therapy
L Bezu, O Kepp, G Cerrato, J Pol, J Fucikova, R Spisek, L Zitvogel, ...
Oncoimmunology 7 (12), e1511506, 2018
1562018
Trial watch: Oncolytic viruses for cancer therapy
J Pol, N Bloy, F Obrist, A Eggermont, J Galon, I Cremer, P Erbs, ...
Oncoimmunology 3 (6), e28694, 2014
1512014
Trial Watch—Oncolytic viruses and cancer therapy
J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ...
Oncoimmunology 5 (2), e1117740, 2016
1392016
Trial Watch: Peptide-based anticancer vaccines
J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ...
Oncoimmunology 4 (4), e974411, 2015
1392015
Effects of interleukin-2 in immunostimulation and immunosuppression
JG Pol, P Caudana, J Paillet, E Piaggio, G Kroemer
The Journal of Experimental Medicine 217 (1), 2020
1292020
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy
BW Bridle, L Chen, CG Lemay, JS Diallo, J Pol, A Nguyen, A Capretta, ...
Molecular Therapy 21 (4), 887-94, 2013
1252013
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy
ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman
Molecular Therapy 22 (1), 123-131, 2014
1232014
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
S Gujar, JG Pol, G Kroemer
OncoImmunology, e1442169, 2018
1172018
Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance
N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ...
Immunological reviews 280 (1), 165-174, 2017
942017
Metabolic vulnerability of cisplatin‐resistant cancers
F Obrist, J Michels, S Durand, A Chery, J Pol, S Levesque, A Joseph, ...
The EMBO journal 37 (14), e98597, 2018
922018
Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity
JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ...
Cell Metabolism 30 (4), 754-767. e9, 2019
882019
S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3
F Wang, T Alain, KJ Szretter, K Stephenson, JG Pol, MJ Atherton, ...
Nature immunology 17 (5), 514-522, 2016
862016
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20